Forma Therapeutics Holdings, Inc.
FMTX evidence brief
What we can confirm
- BioSniper Score:
- 7.9 / 10
- Lead Asset:
- etavopivat (Phase 2)
What it means
What to watch
Prepared research question
What matters most for FMTX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Tracking 4 pipeline candidates for Forma Therapeutics Holdings, Inc..
Run Forma Therapeutics Holdings, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Forma Therapeutics Holdings, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 2/Phase 3
4 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Governance
Frequently asked questions
What is Forma Therapeutics Holdings, Inc.'s lead drug candidate?
Forma Therapeutics Holdings, Inc.'s most advanced tracked candidate is etavopivat (Phase 2) for Sickle Cell Disease; Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R.
Who is the CEO of Forma Therapeutics Holdings, Inc.?
Frank D. Lee is the chief executive officer of Forma Therapeutics Holdings, Inc. (FMTX).
What therapeutic areas does Forma Therapeutics Holdings, Inc. focus on?
Forma Therapeutics Holdings, Inc. develops therapies across Oncology, Rare Disease, Infectious Disease, Metabolic, Hematology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.